OTCMKTS:BIOVF Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Price, News & Analysis $30.29 0.00 (0.00%) As of 05/29/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestBuy This Stock About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BIOVF alerts:Sign Up Key Stats Today's Range$30.29▼$30.2950-Day Range$25.80▼$30.6652-Week Range$24.08▼$32.25VolumeN/AAverage Volume600 shsMarket Capitalization$10.78 billionP/E Ratio29.13Dividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewSwedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.Read More… Receive BIOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOVF Stock News HeadlinesSwedish Orphan Biovitrum: Haematology Focus Seems To Be Paying OffMay 22, 2025 | seekingalpha.comSwedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call TranscriptApril 29, 2025 | seekingalpha.comCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…May 30, 2025 | Investors Alley (Ad)Sobi publishes Q1 2025 report: Portfolio continues to deliverApril 29, 2025 | finance.yahoo.comDNB MARKETS Upgrades Swedish Orphan Biovitrum AB (BIOVF)April 9, 2025 | msn.comNotice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)April 1, 2025 | prnewswire.comSobi publishes Annual and sustainability report for 2024March 31, 2025 | finance.yahoo.comBerenberg Bank Sticks to Its Buy Rating for Swedish Orphan Biovitrum AB (0MTD)February 18, 2025 | markets.businessinsider.comSee More Headlines BIOVF Stock Analysis - Frequently Asked Questions How have BIOVF shares performed this year? Swedish Orphan Biovitrum AB (publ)'s stock was trading at $27.66 on January 1st, 2025. Since then, BIOVF shares have increased by 9.5% and is now trading at $30.29. View the best growth stocks for 2025 here. How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter? Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) released its earnings results on Tuesday, April, 29th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $0.04. The firm had revenue of $641.33 million for the quarter, compared to the consensus estimate of $644.12 million. Swedish Orphan Biovitrum AB (publ) had a net margin of 14.89% and a trailing twelve-month return on equity of 10.91%. How do I buy shares of Swedish Orphan Biovitrum AB (publ)? Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings4/29/2025Today5/30/2025Next Earnings (Estimated)7/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:BIOVF CIKN/A Webwww.sobi.com Phone(468) 697-2000FaxN/AEmployees1,772Year Founded2001Profitability EPS (Most Recent Fiscal Year)$1.06 Trailing P/E Ratio29.13 Forward P/E RatioN/A P/E GrowthN/ANet Income$367.51 million Net Margins14.89% Pretax Margin16.68% Return on Equity10.91% Return on Assets5.42% Debt Debt-to-Equity Ratio0.31 Current Ratio0.91 Quick Ratio0.62 Sales & Book Value Annual Sales$2.46 billion Price / Sales4.38 Cash Flow$1.89 per share Price / Cash Flow16.01 Book Value$10.82 per share Price / Book2.80Miscellaneous Outstanding Shares356,000,000Free FloatN/AMarket Cap$10.78 billion OptionableNot Optionable Beta0.50 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (OTCMKTS:BIOVF) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Swedish Orphan Biovitrum AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Swedish Orphan Biovitrum AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.